23 Jul, 2026
According to Straits Research, the global stem cell umbilical cord blood market size was valued at $17.94 billion in 2025 and is projected to grow from $18.79 billion in 2026 to $27.2 billion by 2034, at a CAGR of 4.73% during the forecast period 2026–2034.
The market for stem cells derived from umbilical cord blood is expected to grow rapidly in the near future. Cord blood, a rich source of stem cells, is discarded after pregnancy or childbirth, even though it has the potential to effectively treat chronic diseases like cancer, diabetes, blood diseases, and immune disorders. More than 80 genetic diseases are currently treated using hematopoietic stem cells from cord blood. Due to numerous governments funding cord blood stem cell research and clinical trials, healthcare organizations have increased their investments in the study and commercialization of cord blood stem cell therapies.
Cord blood stem cells can treat a number of chronic diseases, such as solid tumor cancer, blood cancer, CNS disease, immune diseases, and other uncommon metabolic diseases. Combination stem cell therapy is used to treat diseases that cannot be treated with standard therapies or have side effects. Particularly in oncology treatment, combination therapies are used. For instance, the patients receive anti-cancer medications following the transplant in a treatment that aids in destroying cancer cells. These medications aid the patient in eliminating any cancer cells that might be present. In these situations, the stem cell functions as a healing agent to repair the harm caused by treatment doses. The market will grow due to rising demand, increased awareness, and ongoing research and development for vaccines against various diseases.
Although using stem cells to deliver treatments is expensive, other related procedures, like gathering and storing cells, can be done so at a reasonable cost. Stem cell therapies must be more cost-effective to compete effectively with conventional treatments. The market for stem cells demonstrates expanding opportunities in therapeutics by lowering the cost of treatment operations and monitoring. Similar to how access to treatment creates expanding market opportunities.
North America dominates the stem cell umbilical cord blood market, registering a CAGR of 16.3%. Patients with diabetes, cancer and other diseases are treated with stem cell-rich umbilical cord blood. In North America, the healthcare system is indispensable for the long-term economic stability of stem cell banking. The market for stem cells from umbilical cord blood had the largest contribution from diabetes. Several experimental strategies are being used to attack the immune system's beta cells. New cell-based treatments for diabetes are being created and tested in clinical trials that adhere to legal requirements, like those advised by the US Food and Drug Administration.
The European market for stem cell umbilical cord blood is growing with a CAGR of 15.6%. Stem cell research is one of the existing fields of study and can potentially treat diseases, such as degenerative diseases, for which there are currently few treatments. The widespread use of stem cell storage services and the continued use of these cells in fields like regenerative medicine and transplant medicine are the factors driving the growth of the stem cell umbilical cord blood market in Europe. The need for stem cell storage has been made possible by the growing number of clinical uses of stem cells in treating chronic illnesses. European companies are offering services that can be used as additional treatments, such as genetic and fertility-assisted testing linked to stem cell storage. Additionally, rising transplants of damaged own stem cells will fuel the market during the anticipated time frame.
Asia-Pacific provides lucrative opportunities for stem cell therapies due to the region's extensive drug pipelines in cell-based therapies and large patient population. The Asia-Pacific region is anticipated to grow at a significant rate of 16.7%. The majority of Asian nations are revolutionizing stem cell research. Researchers and scientists have created a new opportunity to investigate diseases and develop diagnostic and research techniques. Although promising, stem cell research is still in its infancy, and few human trials have been conducted. However, researchers are already enthusiastic about its potential impact on regenerative medicine. Stem cells are currently the subject of a growing number of clinical trials aimed at curing numerous age-related diseases and delaying aging. Diabetes, cardiovascular disease, HIV/AIDS, hepatitis, arthritis, and cancer, which are prevalent in the developing world, may soon be treatable using stem cells, according to medical researchers.
The LAMEA market is anticipated to expand at a rapid rate due to an increase in public awareness of stem cell umbilical cord blood storage. The market will likely face new obstacles in terms of transplantation costs, donor availability, the number of centers of excellence, and trained personnel, which must be addressed for the region's growth in this field. This region's limited service availability will inhibit market expansion.
sales@straitsresearch.com